Shedir Pharma S p A : GROUP – PRESENTATION (MAY 2021)

GROUP PRESENTATION (MAY 2021)

• Company and Market Overview

Shedir Pharma Group - What we do

Shedir Group is focused on the development, formulation, distribution and sale of dietary supplements and drugs

 The Group has organized its activities within 2 Business Units supported by captive companies operating in certain R&D and marketing activities

Business Unit 1 - Shedir division

• Shedir division is involved in the development, formulation, distribution and sale of supplements, dermocosmetics and medical devices
• Within the division, Shedir Pharma Srl is engaged in the products distribution, through 4 product lines, with exclusive sales agents involved in the release to healthcare professionals (doctors and pharmacists )
• In April 2019, the Group launched new line Shedir Pet, to expand its products offer and to penetrate a growing market

5	® 90+
Product
Lines	Brands
~600	300+
Exclusive	References
sales agents

Business Unit 2 - Dymalife division

 Dymalife division is involved in the development, formulation, distribution and sale of drugs and, marginally, dietary supplments.

 In 2017, the Group entered in the pharmaceutical sector through the acquisition of pharmaceutical assets and the costitution of Dymalife Pharmaceutical Srl.

 Dymalife Pharmaceutical sells group A, group C and OTC medicines, through two specific product lines: Dyma and Horizon. In order to offer a complete therapeutic treatment, the Company enriched these lines with supplements and medical devices.

® 30+

2Brands

Product

Lines100+

~100 References

Exclusive

sales agents	29
	AIC(1)

An integrated offer of nutraceuticals and drugs

Notes: (1) Value as of May 2021

3

Shedir Pharma Group - History

Key milestones
Wholesale distribution	Nutraceutical Consolidation		Diversification
2008	2011	2015	2017	2019	2020

Main activities

• Shedir establishment and start-up
• Warehouse, logistic and administration insourcing in Sorrento peninsula (2008)
• Sales force recruitment
• Launch of the first line of products Shedir (2008)

• Launch of the second line of products Deimos (2011)
• New headquarter 500 sqm in Piano di Sorrento (2011)
• New warehousing and logistic facilities 3.500 sqm located in Mercato San Severino (2012)
• Launch of the third and fourth line of products Phobos and Menkar (2014)
• Warehouse extension of around 5.000 sqm (2014)

• Neilos (R&D) establishment (2015)
• Filing for first patent (2015)
• Product brands transferred to Neilos (2015)
• Adhara Marketing and Comunication acquisition (2015)
• Shedir Farmaceutica España SL establishment (2015)
• Start of internationalization process (2016)
• First clinical study published an international paper (2016)

• Launch of the fifth line, Green Planet, dedicated to pharmacies through direct marketing strategy (2017)
• Dymalife (Pharma) establishment with the first line Dyma (2017)
• Launch of the second line of Dymalife, Horizon (2018)
• Launch of the sixth line of Shedir Pharma, Shedir Pet (2019) dedicated to veterinarians
• IPO (July, 2019) on AIM

COVID situation doesn't stop internal and external development of the Gruop:

• Dymalife buys EMINOCS (diclofenac of potassium specialty);
• Group continues its R&D activities through Neilos reaching over 30 patents (and over 60 pending)

# agents # references

20+

60+

130+

170+

~400

30+

220+

500+

600+

~700

A young, dynamic and fast-growing company

4

Successful Asset-light Business Model

The Group oversees the entire value chain, from R&D to products' distribution

Concept	Regulatory	Formulation
Development	Compliance

In-House

Production	Warehousing
and Logistics

Outsourced

Marketing	Sales &
Distribution

In-House

• Experienced R&D team with 8 people
• Feedback from doctors and pharmacists
• Collaboration with oustanding pharmaceutical players
• Collaboration with universities and academies
• Opinion leader surveys and papers

• Innovative products with new formulation/composition
• Clinical trials with the support of primary clinical research centres
• Regulatory compliance
• Technical documentation preparation

• Direct access to high-quality raw materials: procurement of the core raw material from selected suppliers is carried out directly by the Group
• ~40 third-party specialized factories in Italy with whom Shedir has built longstanding relationship
• Quality control on the whole production chain and compliant with pharma standards

• Promotional activities addressed to doctors and pharmacists
• Advertisement and Communication
• Conventions oriented to divulgation and introduction of new products
• Sales to:
• • wholesalers operating on a domestic scale
  • pharmacies and parapharmacies thanks to a widespread network of exclusive sales agents

31	~ 30	50+
Patents	References/
Patents
pending	year

• Delivering high quality products

~1.2%

Net Capex(2)

/Total Sales

(2019)

• Flexible production system in terms of limited investments required and high adaptability to client needs

#2

of doctor

contacts(1)

• First mover in market niches

Focus on the value-added activities along the value chain

Source (1)	ABACAM	5
Notes (2)	Net CAPEX excluding extraordinary capital expenditure